TheranosticTrials.org

Clinical Trial · NCT07498933

FAP-targeted PET/NIR in Lung Malignant Tumors

Overview

Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.

Sponsor

Peking University First Hospital

Contacts

Yuan Li, MD (PRINCIPAL_INVESTIGATOR)

Qingyun Liu, MD (CONTACT)

qingyun_liu919@163.com

Kezhong Chen, MD (CONTACT)

mdkzchen@163.com

+86-010-88325983

Jun Wang, M.M. (STUDY_CHAIR)

Kezhong Chen, MD (STUDY_DIRECTOR)

Zhaohui Zhu, MD (PRINCIPAL_INVESTIGATOR)

Hao Li, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07498933

Drug / Compound

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • Able to retain sufficient tumor tissue for testing and research;
  • Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;
  • * Age between 18 and 70 years old;
  • Have complete clinical and imaging data;
  • Sign informed consent.

Exclusion

  • The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing;
  • Lack of clinical and imaging data;
  • * Previously combined with other malignant tumors or received other anti-tumor treatments;
  • The duration of neoadjuvant therapy is less than 3 cycles;
  • Failure to collect sufficient tumor tissue for testing and research;